Corcept Therapeutics (CORT) Projected to Post Earnings on Thursday

Corcept Therapeutics (NASDAQ:CORT) is expected to announce its earnings results before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of $0.37 per share and revenue of $198.88 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Corcept Therapeutics Trading Up 3.0 %

Shares of Corcept Therapeutics stock opened at $70.15 on Thursday. The business has a fifty day simple moving average of $57.45 and a two-hundred day simple moving average of $48.88. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $71.29. The company has a market capitalization of $7.35 billion, a price-to-earnings ratio of 55.68 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on CORT shares. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Corcept Therapeutics in a report on Friday, February 7th. Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Canaccord Genuity Group lifted their target price on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. Finally, StockNews.com downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics has a consensus rating of “Buy” and an average target price of $88.25.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $59.46, for a total value of $130,812.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. This trade represents a 18.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,011 shares of company stock valued at $1,479,608 over the last ninety days. 20.50% of the stock is owned by company insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.